DRTS vs. LQDA, ESTA, FNA, EYE, AXGN, CBLL, BVS, AVNS, IRMD, and BFLY
Should you be buying Alpha Tau Medical stock or one of its competitors? The main competitors of Alpha Tau Medical include Liquidia (LQDA), Establishment Labs (ESTA), Paragon 28 (FNA), National Vision (EYE), AxoGen (AXGN), CeriBell (CBLL), Bioventus (BVS), Avanos Medical (AVNS), Iradimed (IRMD), and Butterfly Network (BFLY). These companies are all part of the "medical equipment" industry.
Alpha Tau Medical vs.
Alpha Tau Medical (NASDAQ:DRTS) and Liquidia (NASDAQ:LQDA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, community ranking, profitability and institutional ownership.
Liquidia received 183 more outperform votes than Alpha Tau Medical when rated by MarketBeat users. However, 70.37% of users gave Alpha Tau Medical an outperform vote while only 68.24% of users gave Liquidia an outperform vote.
In the previous week, Liquidia had 10 more articles in the media than Alpha Tau Medical. MarketBeat recorded 11 mentions for Liquidia and 1 mentions for Alpha Tau Medical. Alpha Tau Medical's average media sentiment score of 0.47 beat Liquidia's score of 0.35 indicating that Alpha Tau Medical is being referred to more favorably in the media.
Alpha Tau Medical has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Comparatively, Liquidia has a beta of 0.23, indicating that its stock price is 77% less volatile than the S&P 500.
Alpha Tau Medical presently has a consensus price target of $8.00, indicating a potential upside of 104.60%. Liquidia has a consensus price target of $25.38, indicating a potential upside of 96.86%. Given Alpha Tau Medical's higher probable upside, equities research analysts clearly believe Alpha Tau Medical is more favorable than Liquidia.
Alpha Tau Medical has a net margin of 0.00% compared to Liquidia's net margin of -765.38%. Alpha Tau Medical's return on equity of -38.62% beat Liquidia's return on equity.
2.7% of Alpha Tau Medical shares are owned by institutional investors. Comparatively, 64.5% of Liquidia shares are owned by institutional investors. 39.5% of Alpha Tau Medical shares are owned by insiders. Comparatively, 30.1% of Liquidia shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Alpha Tau Medical has higher earnings, but lower revenue than Liquidia. Alpha Tau Medical is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.
Summary
Alpha Tau Medical beats Liquidia on 10 of the 18 factors compared between the two stocks.
Get Alpha Tau Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for DRTS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alpha Tau Medical Competitors List
Related Companies and Tools
This page (NASDAQ:DRTS) was last updated on 1/21/2025 by MarketBeat.com Staff
Free DRTS Stock Alerts